• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AVIR

    Atea Pharmaceuticals Inc.

    Subscribe to $AVIR
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: ateapharma.com

    Peers

    $ALBO
    $KZR
    $OYST

    Recent Analyst Ratings for Atea Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    10/20/2021$60.00 → $20.00Outperform
    SVB Leerink
    10/20/2021$61.00 → $16.00Overweight → Neutral
    JP Morgan
    See more ratings

    Atea Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

      4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 2:30:36 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 8:03:19 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care